X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3268) 3268
Publication (309) 309
Newsletter (21) 21
Book Review (13) 13
Book Chapter (12) 12
Conference Proceeding (10) 10
Dissertation (4) 4
Book / eBook (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3142) 3142
female (2794) 2794
ovarian neoplasms - enzymology (1995) 1995
oncology (1504) 1504
index medicus (1221) 1221
ovarian neoplasms - pathology (1117) 1117
ovarian cancer (980) 980
cell line, tumor (880) 880
animals (832) 832
cancer (776) 776
middle aged (776) 776
adult (657) 657
expression (623) 623
aged (588) 588
ovarian neoplasms - drug therapy (572) 572
ovarian neoplasms - genetics (563) 563
mice (528) 528
ovarian-cancer (503) 503
immunohistochemistry (474) 474
male (414) 414
apoptosis (402) 402
carcinoma (397) 397
tumor cells, cultured (390) 390
prognosis (354) 354
tumors (349) 349
cell biology (322) 322
obstetrics & gynecology (319) 319
breast-cancer (311) 311
ovarian neoplasms - metabolism (309) 309
biochemistry & molecular biology (308) 308
antineoplastic agents - pharmacology (302) 302
research (295) 295
metastasis (286) 286
neoplasms - enzymology (286) 286
chemotherapy (284) 284
gene expression regulation, neoplastic (277) 277
breast neoplasms - enzymology (267) 267
proteins (248) 248
apoptosis - drug effects (246) 246
cells (246) 246
neoplasm staging (241) 241
analysis (236) 236
aged, 80 and over (232) 232
mice, nude (231) 231
signal transduction (231) 231
phosphorylation (229) 229
transfection (229) 229
gene expression (227) 227
activation (216) 216
neoplasm invasiveness (212) 212
pathology (211) 211
blotting, western (206) 206
breast cancer (206) 206
article (205) 205
cell proliferation (193) 193
research article (191) 191
genetic aspects (190) 190
cell proliferation - drug effects (188) 188
adenocarcinoma - enzymology (185) 185
care and treatment (181) 181
drug resistance, neoplasm (181) 181
health aspects (177) 177
medicine (177) 177
rna, messenger - genetics (174) 174
enzymes (173) 173
growth (172) 172
ovarian carcinoma (172) 172
cisplatin - pharmacology (171) 171
development and progression (168) 168
kinases (167) 167
pharmacology & pharmacy (167) 167
time factors (162) 162
antineoplastic agents - therapeutic use (160) 160
cisplatin (160) 160
mutation (160) 160
reverse transcriptase polymerase chain reaction (155) 155
dose-response relationship, drug (154) 154
survival (154) 154
carcinoma - enzymology (151) 151
signal transduction - drug effects (151) 151
enzyme inhibitors - pharmacology (150) 150
xenograft model antitumor assays (149) 149
invasion (146) 146
biomarkers, tumor - metabolism (145) 145
gene (144) 144
inhibition (144) 144
ovary - enzymology (144) 144
hematology, oncology and palliative medicine (142) 142
medicine, research & experimental (141) 141
multidisciplinary sciences (141) 141
rna, messenger - metabolism (136) 136
physiological aspects (135) 135
enzyme activation (132) 132
proto-oncogene proteins c-akt - metabolism (128) 128
breast neoplasms - genetics (127) 127
biology (125) 125
in-vitro (125) 125
science (125) 125
gene expression regulation, enzymologic (124) 124
neoplasm metastasis (124) 124
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3066) 3066
German (53) 53
Chinese (51) 51
Russian (46) 46
Japanese (33) 33
French (14) 14
Italian (9) 9
Polish (9) 9
Spanish (4) 4
Czech (3) 3
Bulgarian (1) 1
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2512 - 2519
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 852 - 861
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | BRCA2 MUTATIONS | LIPOSOMAL DOXORUBICIN | RIBOSE POLYMERASE INHIBITORS | SOLID TUMORS | ONCOLOGY | GENETICS | GUIDELINES | SENSITIVITY | RESISTANCE | PARP INHIBITOR | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Aged, 80 and over | Cell Differentiation | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Administration, Oral | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Canada | Breast Neoplasms - genetics | Carcinoma - genetics | Mutation | Receptor, ErbB-2 - analysis | Piperazines - administration & dosage | Receptors, Estrogen - analysis | Ovarian Neoplasms - mortality | Breast Neoplasms - enzymology | Antineoplastic Agents - adverse effects | Carcinoma - enzymology | Adult | Female | Ovarian Neoplasms - drug therapy | Carcinoma - secondary | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | BRCA1 Protein - genetics | Disease-Free Survival | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | BRCA2 Protein - genetics | Phthalazines - adverse effects | Care and treatment | Relapse | Gene mutations | Oncology, Experimental | Breast cancer | Research | Cancer | Diseases | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 08/2010, Volume 466, Issue 7308, pp. 869 - 873
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
Biological Chemistry, ISSN 1431-6730, 05/2012, Volume 393, Issue 5, pp. 301 - 317
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2012, Volume 127, Issue 1, pp. 63 - 69
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2012, Volume 21, Issue 2, pp. 227 - 239
Journal Article
International Journal of Clinical and Experimental Pathology, ISSN 1936-2625, 2014, Volume 7, Issue 8, pp. 5057 - 5070
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 02/2013, Volume 366, Issue 2, pp. 170 - 179
► AMPK has an emerging role in the regulation of endocrine-related cancer cell growth. ► In most cases, AMPK is a negative regulator of cancer cell... 
AMPK | Breast cancer | Colon cancer | Endometrial cancer | Prostate cancer | Ovarian cancer | SIGNALING PATHWAYS | TRANSCRIPTIONAL ACTIVITY | ACTIVATED PROTEIN-KINASE | INDUCED APOPTOSIS | BOVINE GRANULOSA-CELLS | DU145 PROSTATE CARCINOMA | POSTMENOPAUSAL BREAST-CANCER | CELL BIOLOGY | 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOSIDE | ENDOCRINOLOGY & METABOLISM | BODY-MASS INDEX | KAPPA-B PATHWAY | AMP-Activated Protein Kinases - metabolism | Colonic Neoplasms - genetics | Metformin - therapeutic use | Colonic Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Male | Obesity - genetics | Ovarian Neoplasms - genetics | Prostatic Neoplasms - genetics | Endometrial Neoplasms - genetics | Endocrine System - drug effects | Female | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Hypoglycemic Agents - therapeutic use | Endometrial Neoplasms - enzymology | Metformin - pharmacology | Ovarian Neoplasms - enzymology | Endocrine System - pathology | Hypoglycemic Agents - pharmacology | Cell Transformation, Neoplastic | Prostatic Neoplasms - enzymology | Endometrial Neoplasms - drug therapy | Colonic Neoplasms - enzymology | Obesity - enzymology | Endocrine System - enzymology | AMP-Activated Protein Kinases - genetics | Biological Factors - pharmacology | Physiological aspects | Care and treatment | Tumor proteins | Cancer
Journal Article